Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2014011091
pages 133-141

NK Cells in Therapy of Cancer

Veronika Bachanova
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN
Jeffrey S. Miller
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN

SINOPSIS

Natural killer (NK) cells recognize targets stressed by malignant transformation or infection and can be long-lived. They become educated by interacting with major histocompatibility antigen (MHC) class I molecules to gain function to kill targets and produce cytokines. In the clinic, haploidentical NK cells can be adoptively transferred to treat cancer. Persistence and in vivo expansion of NK cells depends on lymphodepleting chemotherapy to make space and induce release of endogenous IL-15. In vivo expansion is also enhanced by cytokine administration but IL-2 has the down side of stimulating CD25hi regulatory T cells (Tregs). Other limitations to NK-cell therapy include poor in vivo survival and lack of specificity. Bispecific or trispecific killer engagers that target CD16 on NK cells to enhance recognition of tumor antigens, and desintegrin and metalloproteinase 17 (ADAM17) inhibition that prevents CD16 shedding after NK-cell activation should promote enhanced killing of cancer with specificity. These are exciting times; more than 35 years after NK cells were initially described, we are exploiting their capacity for clinical therapy.


Articles with similar content:

Dendritic Cells, Interleukin 12, and CD4+ Lymphocytes in the Initiation of Class l-restricted Reactivity to a Tumor/Self Peptide
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Emira Ayroldi, Maria Laura Belladonna, Maria Cristina Fioretti, Daniela Surace, Silvia Silla, Paolo Puccetti, Ursula Grohmann, Roberta Bianchi
Elimination of Virus-Specific Cytotoxic T Cells in the Liver
Critical Reviews™ in Immunology, Vol.22, 2002, issue 1
Gunther Dennert
Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies
Critical Reviews™ in Immunology, Vol.37, 2017, issue 1
Toshiaki Kikuchi, Toshiyuki Koya, Masashi Arita, Miho Takahashi, Yu Saida, Satoshi Watanabe
Quantitating Therapeutically Relevant T-Cell Responses to Cancer Vaccines
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
H. Kim Lyerly, Michael A. Morse, Timothy M. Clay, Paul J. Mosca, Amy C. Hobeika
Strategies to enhance NK cell function for the treatment of tumors and infections
Critical Reviews™ in Immunology, Vol.38, 2018, issue 2
Taku Kambayashi, Jacquelyn Freund-Brown, Leilani Chirino